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Abstract: There is a lack of predictive markers for early and rapid identification of disease progression
in COVID-19 patients. Our study aims at identifying microRNAs (miRNAs)/small nucleolar RNAs
(snoRNAs) as potential biomarkers of COVID-19 severity. Using differential expression analysis of
microarray data (n = 29), we identified hsa-miR-1246, ACA40, hsa-miR-4532, hsa-miR-145-5p, and
ACA18 as the top five differentially expressed transcripts in severe versus asymptomatic, and ACA40,
hsa-miR-3609, ENSG00000212378 (SNORD78), hsa-miR-1231, hsa-miR-885-3p as the most significant
five in severe versus mild cases. Moreover, we found that white blood cell (WBC) count, absolute
neutrophil count (ANC), neutrophil (%), lymphocyte (%), red blood cell (RBC) count, hemoglobin,
hematocrit, D-Dimer, and albumin are significantly correlated with the identified differentially
expressed miRNAs and snoRNAs. We report a unique miRNA and snoRNA profile that is associated
with a higher risk of severity in a cohort of SARS-CoV-2 infected patients. Altogether, we present a
differential expression analysis of COVID-19-associated microRNA (miRNA)/small nucleolar RNA
(snoRNA) signature, highlighting their importance in SARS-CoV-2 infection.
Keywords: snoRNA; miRNA; SARS-CoV-2; COVID-19; biomarkers
1. Introduction
At the beginning of 2020, the World Health Organization (WHO) declared coronavirus
disease-2019 (COVID-19) as a global pandemic. The causative organism, severe acute
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respiratory syndrome coronavirus 2 (SARS-CoV-2), exhibits a wide spectrum of clinical
manifestations in disease-ridden patients. Differences in the severity of COVID-19 ranges
from asymptomatic infections and mild cases to the severe form, leading to acute respira-
tory distress syndrome (ARDS) and multiorgan failure with poor survival [1]. Moreover,
the mortality rate is influenced by aging, viral strain, pre-existing comorbidities, and the
degree of immunocompromise. Indeed, the health and socioeconomic implications of the
COVID-19 pandemic are enormous, and thus warrants the search for new interventions
and treatment measures. Recent research has suggested that a unique non-coding RNA
signature can aid in identifying the likelihood of developing specific disease outcomes [2].
Alterations of miRNA levels in the blood have been described in multiple inflammatory
and infectious diseases, including SARS-related coronaviruses [3–9]. MiRNAs are endoge-
nous small non-coding RNAs, around 22 nucleotides, that bind specific messenger RNAs
(mRNAs) through complementary base-pairing [10]. Hence, miRNAs can regulate various
cellular processes, including proliferation, apoptosis, and differentiation, by binding to the
3′UTR of target mRNAs inducing their degradation, thus serving a fundamental role in
post-transcriptional repression [11,12]. In this context, a single miRNA can target several
genes, and multiple miRNAs may regulate a single gene. Hence, identification of miRNAs
as well as characterization of miRNA-mRNA interactions in SARS-CoV-2 infection is im-
portant to understand their role in disease pathogenesis, progression, and severity [13–15].
Accumulating evidence is also implicating snoRNAs in numerous physiological and patho-
logical processes, including their interactions with some RNA viruses [16,17]. SnoRNAs
have been shown to play a role in ribosomal RNAs (rRNAs) modification and maturation.
These include pseudouridylation, 2′-O-methylation, polyadenylation, alternative splic-
ing, and formation of protein complexes with fibrillarin that is a component of several
ribonucleoproteins [18]. There are no reports yet with a comprehensive characterization of
snoRNAs in SARS-CoV-2 infection. Here, we report for the first time the snoRNA signature,
and similar to previous studies the miRNA signature in the peripheral blood of severe
COVID-19 cases (n = 9), as compared to mild (n = 10) and asymptomatic (n = 10) patients.
This study analyzed a total of 29 COVID-19 patients that were matched for age and comor-
bidities using Affymetrix GeneChip miRNA 4.0 array and were recruited between July and
October 2020 in Qatar.
2. Materials and Methods
2.1. Study Design and Data Collection
This research is in accordance with the Reporting of Observational Studies in Epidemi-
ology (STROBE) recommendations, the Code of Ethics of the World Medical Association.
This study was granted ethical approval from the Medical Research Center at Hamad
Medical Corporation (MRC-05-084, Immunological and immune-genetic investigations in
COVID-19 patients with varying disease severity, 06/21/2020). All study participants gave
written informed consent where possible, and deferred consent was obtained for ICU cases.
From 173 recruited patients in this prospective cohort study, 29 male age-matched patients
were included. All patients were previously diagnosed with COVID-19 using TaqPath
COVID-19 Combo Kit (Thermo Fisher Scientific, Waltham, MA, USA), or Cobas SARS-
CoV-2 Test (Roche Diagnostics, Rotkreuz, Switzerland), with a CT value < 30. Additional
criterion for selection was age between 35 and 75 years. Participants were grouped into
severe, mild, and asymptomatic. Classifying severe cases was based on the requirement of
high-flow oxygen support and ICU admission (n = 9). Whereas mild patients were identi-
fied based on symptoms, and positive radiographic findings with pulmonary involvement
(n = 10). Patients with no clinical presentation were labelled as asymptomatic cases (n = 10).
In the severe group, three patients died with respiratory failure listed as the primary cause
of death. Blood samples were collected in the PAXgene Blood RNA Tubes (PreAnalytiX) at
the time of diagnosis, prior to isolation, or hospitalization. Routine laboratory tests that
were performed include complete blood cell counts, electrolytes, glucose, albumin, total
protein, C-reactive protein, procalcitonin, IL-6, D-dimers, ferritin, urea, and liver enzymes.
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2.2. RNA Isolation and Quality Control
Peripheral venous blood (2.5 mL) in PaX gene tubes was inverted 8–10 times to en-
sure complete mixing with the lysis reagent. Tubes were then stored upright at room
temperature for a minimum of 2 h, before transferring them to a freezer at −80 ◦C until
RNA isolation. The RNA (both total and miRNA) was isolated with a blood miRNA kit
from Qiagen (PreAnalytiX GmBH Hombrechtikon, Switzerland) following the manufac-
turer’s instructions. The concentrations and purity of the RNA samples were evaluated
spectrophotometrically (Nanodrop ND-1000, Thermo, Wilmington, DE, USA). The RNA
isolation process was validated by analyzing the integrity of RNA with the RNA 6000
Nano Chip Kit (Agilent, CA, USA); the presence of the small RNA fraction was confirmed
by the Agilent Small RNA Kit (Agilent).
2.3. Microarray and Data Analysis
Affymetrix GeneChip miRNA 4.0 array was used following the manufacturer’s in-
structions for miRNA expression analysis. For each sample, 250 ng of RNA was labelled
using the FlashTag™ Biotin RNA Labeling Kit (Genisphere, Hatfield, PA, USA). Following
this, the labelled RNA was quantified, fractionated, and hybridized to the miRNA microar-
ray with continuous agitation at 60 rpm for 16 h at 48 ◦C on a GeneChip Hybridization
Oven 640. The miRNA microarray chips were then washed and stained using the GeneChip
Fluidics Station 450 (Affymetrix, Santa Clara, CA, USA). Finally, the miRNA microarray
chips were scanned using an Affymetrix GCS 3000 scanner (Affymetrix, Santa Clara, CA,
USA), and the signal values were evaluated using the Affymetrix® GeneChip™ Command
Console software.
Raw data were extracted using the Affymetrix data extraction protocol in the Affymetrix
GeneChip® Command Console® (AGCC) Software. All statistical analyses including raw
data import, annotation, and quality control were conducted with R statistical software
(version 4.0.4, R Foundation, Boston, MA, USA). R Bioconductor packages “oligo” [19],
“oligoCalsses”, and “BioBase” were used for the pre-processing of microarray datasets [20].
Raw expression data in CEL files were read and parsed into ExpressionFeatureSet using
the “read.celfiles” function, followed by sample and probe annotations with “Annotated-
DataFrame” function. Next background correction, normalization, and log2 transformation
using the robust multiarray average (RMA) method was performed. The differentially
expressed transcripts were screened out via the “limma” package [21]. The analysis was
performed using the design matrix “~severity” as a factor, where it was either “asymp-
tomatic”, “mild” or “severe”. A comparative analysis between different severity groups
was carried out using thresholds of |log2FC| > 1.5 and FDR < 0.05. Hierarchical clustering
of differentially expressed miRNAs was carried out using the “pheatmap” R package.
The prediction of miRNA-target genes was performed using the “multiMiR” R package
filtering with validated databases, including miRecords, miRTarBase, and TarBase, and
the list of 26 differentially expressed miRNAs in severe vs asymptomatic and severe vs
mild comparisons [22]. The package “miRBaseConverter” was used to retrieve the miRNA
sequence based on the accession number [23]. The database miRTarBase was used with a
threshold of 2 for the minimum number of miRNA-target interactions, 1 for the adjusted
p-value (FDR), and with filter by evidence categories set to strong [24]. The miRNA-target
genes network was built using the “MIENTURNET” tool [25], while the final network
was visualized using Cytoscape software [26]. Functional enrichment analysis of target
genes list was performed using the “Enrichr” platform including Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway enrichment analysis. Spearman rank correlation
tests were calculated to assess the correlation between blood parameters and the levels of
DE miRNAs and snoRNAs employing “ggstatsplot” R package. Other helper packages
in plotting and formatting include “dplyr”, “kableExtra”, “gtsummary”, “flextable”, “of-
ficer”, “grid”, “VennDiagram”, “pheatmap”, “gplots”, “ggplot2”, “stringr”, “reshape2”,
“corrplot”, “tidyr”, “tidyverse”.
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Age was normally distributed and hence mean ± standard deviation was reported.
Since all clinical variables had a non-normal distribution, comparisons between different
groups of severity were performed using the Kruskal–Wallis rank sum test for continuous
variables, and Fisher’s Exact Test for categorical. Clinical values were reported as medians
and interquartile range [IQR]. Two-tailed p-values were calculated, and p-value < 0.05 was
considered statistically significant. The R code that was used to generate the figures and
analysis is available as a supplementary file.
3. Results
First, we identified differentially expressed miRNAs and snoRNAs in severe patients
as compared to mild and asymptomatic cases, a |log2 (fold change)| > 1.5 and an FDR
< 0.05 were used as cutoffs. We found 12 differentially expressed miRNAs and snoRNAs
in severe versus asymptomatic, and 31 differentially regulated miRNAs and snoRNAs
in severe versus mild cases. Of the 4 miRNAs and snoRNAs that were unique in severe
versus asymptomatic, there were 3 upregulated and 1 downregulated transcripts, whereas,
of the 23 uniquely differentially expressed miRNAs and snoRNAs in severe versus mild, 7
were upregulated and 16 downregulated. Interestingly, we also observed 3 miRNAs and
5 snoRNAs that were common in both severe versus mild, and severe versus asymptomatic
comparisons (Figure 1A). Altogether, differential expression (DE) analysis showed a sig-
nature of 27 unique miRNAs and snoRNAs that was associated with COVID-19 severity
(Figure 1B,C). Notably, the most highly differentially expressed miRNAs and snoRNAs
in severe versus asymptomatic are hsa-miR-1246, ACA40, hsa-miR-4532, hsa-miR-145-5p,
and ACA18. Furthermore, the top 5 differentially expressed miRNAs and snoRNAs in se-
vere versus mild are ACA40, hsa-miR-3609, ENSG00000212378 (SNORD78), hsa-miR-1231,
hsa-miR-885-3p (Tables S1 and S2). Additionally, we report for the first time 9 differentially
expressed snoRNAs, namely ACA18 (SNORA18), ACA20 (SNORA20), ACA40 (SNORA40),
ACA57 (SNORA57), ENSG00000212378 (SNORD78), U17b, U44, U78, and U79 (Table S3).
Our novel findings suggest that SARS-CoV-2 infection benefits from gene expression pro-
grams regulated by snoRNAs, including C/D box snoRNAs (SNORDs) and H/ACA box
snoRNAs. Interestingly, no differentially expressed miRNAs or snoRNAs were found in
mild versus asymptomatic comparison with the applied cut-offs. These data suggest that
both miRNAs and snoRNAs dysregulation is associated with a severe form of COVID-19.
Next, we identified putative targets for the identified differentially expressed miRNAs
and snoRNAs in a multi-ethnic cohort of 29 COVID-19 patients residing in Qatar and
presenting with varying disease severity. Then we used miRTarBase package validated
databases (mirecords, mirtarbase, and tarbase) to identify putative pathways that may be
implicated in severe cases of COVID-19. To this end, we used the miRTarBase database,
which is curated with >50,000 miRNA-target interactions and validated experimentally
by reporter assay, Western blot, microarray, and next-generation sequencing. In total,
we found 2584 unique validated target genes for the differentially expressed miRNAs.
The resulting target genes list was used in functional enrichment analyses to identify top
deregulated pathways in severe COVID-19 patients. Remarkably, key enriched KEGG
pathways for the 2584 miRNA-target genes included mainly cancer-related pathways such
as pathways in cancer, hepatocellular carcinoma, chronic myeloid leukemia, microRNAs
in cancer, breast cancer, gastric cancer, pancreatic cancer, colorectal cancer, proteoglycans
in cancer, cellular senescence (Figure 2B). Furthermore, other hallmark gene sets in the
Molecular Signatures Database with important biological implications at the top of the
list include TNF-alpha Signaling via NF-kB, UV Response Dn, IL-2/STAT5 Signaling, Hy-
poxia, Inflammatory Response, Apoptosis, PI3K/AKT/mTOR Signaling, G2-M Checkpoint
(Table S4) [27]. Interestingly, miRNA-target gene network analysis (MTGN) elucidated
7 nodes of differentially expressed miRNAs namely hsa-miR-145-5p, hsa-miR-199a-5p, hsa-
miR-98-5p, hsa-miR-139-5p, hsa-let-7i-5p, hsa-miR-1246, and hsa-miR-572 (Figure 2A,C).
We demonstrate 4 regulated genes targeted by more than 6 differentially expressed miRNAs
(Table S5).
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(A) A Venn diagram of the number of unique and common differentially expressed miRNAs and snoRNAs in severe 
versus asymptomatic (D: grey: upregulated, A: orange: downregulated), and in severe versus mild (C: purple: upregu-
lated, B: green: downregulated). The overlap of the two ovals with upregulated transcripts represents 7 miRNAs and 
snoRNAs shared between the two upregulated lists, and the two ovals with downregulated transcripts represent 1 miRNA 
shared between the two downregulated lists. The areas of no overlap represent the number of uniquely (not shared) miR-
NAs/snoRNAs in each respective comparison, namely 4 in severe versus asymptomatic, and 23 miRNAs/snoRNAs in 
severe versus mild comparison. (B) Volcano plots of differentially expressed miRNAs and snoRNAs, with y-axis as-log10 
adjusted p-value (adjusted for multiple testing with the Benjamini–Hochberg procedure) and x-axis as the log2-fold 
change. The vertical lines represent a threshold of |log2-fold change| > 1.5, either upregulated (right side) or downregu-
lated (left side), while the horizontal lines represent an FDR < 0.05. Each colored point represents an individual probe in 
severe versus asymptomatic comparison (D: green: upregulated, A: orange: downregulated), and in severe versus mild 
comparison (C: purple: upregulated, B: grey: downregulated). (C) Hierarchical clustering of Log2 normalized expression 
values of the differentially expressed miRNAs and snoRNAs in severe versus asymptomatic comparison (n = 25), and in 
severe versus mild (n = 50). 
Figure 1. Differential expression analysis of miRNAs and snoRNAs in asymptomatic, mild, and severe COVID-19 patients.
(A) A Venn diagram of the number of unique and common differentially expressed miRNAs and snoRNAs in severe versus
asymptomatic (D: grey: upregulated, A: orange: downregulated), and in severe versus mild (C: purple: upregulated, B: green:
downregulated). The overlap of the two ovals with upregulated transcripts represents 7 miRNAs and snoRNAs shared
between the two upregulated lists, and the two ovals with downregulated transcripts represent 1 miRNA shared between
the two downregulated lists. The areas of no overlap represent the number of uniquely (not shared) miRNAs/snoRNAs
in each respective comparison, namely 4 in severe versus asymptomatic, and 23 miRNAs/snoRNAs in severe versus
mild comparison. (B) Volcano plots of differentially expressed miRNAs and snoRNAs, with y-axi as-log10 adju ted
p-val e (adjusted for m l iple testing with he Benjamini–Hochberg procedur ) and x-axis as the log2-fold change. The
vertical lines represent a threshold of |log2-fold change| > 1.5, either upregulated (right side) or ownregulated (left side),
while the horizontal lines represent an FDR < 0.05. Each colored point represents an individual probe in severe versus
asymptomatic comparison (D: green: upregulated, A: orange: downregulated), and in severe versus mild comparison
(C: purple: upregulated, B: grey: downregulated). (C) Hierarchical clustering of Log2 normalized expression values of the
differentially expressed miRNAs and snoRNAs in severe versus asymptomatic comparison (n = 25), and in severe versus
mild (n = 50).
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by severe versus asymptomatic, and severe versus mild comparisons. (A) Representation of differentially expressed miR-
NAs and their associated target genes. The name of the miRNA is highlighted in red for upregulated, and in green for 
downregulated, whereas target genes that are highlighted in yellow are those that are targeted by more than 1 miRNA. 
(B) KEGG enrichment analysis with the names of top 10 significant deregulated pathways for KEGG 2021 Human data-
base. The q-value is an adjusted p-value calculated using the Benjamini–Hochberg method for correction for multiple 
hypotheses testing. (C) Network-based visualization of differentially expressed miRNAs and their associated target genes, 
where red/green nodes represent the upregulated/downregulated miRNA, and the blue nodes represent its targeted gene. 
Figure 2. Functional and pathway enrichment analyses using a list of common differentially expressed miRNAs shared
by severe versus asymptomatic, and severe versus mild comparisons. (A) Representation of differentially expressed
miRNAs an their associated target genes. The name of the miRNA is highlighted in red for upregulated, and in green for
downregulated, whereas target genes that are highlighted in yellow are those that are targeted by more than 1 miRNA.
(B) KEGG enrichment analysis with the name of top 10 significant deregulated pathways for KEGG 2021 Human database.
The q-value is an adjusted p-value calculated using the Benjamini–Hochberg method for correction for multiple hypotheses
testing. (C) Network-based visualization of differentially expressed miRNAs and their associated target genes, where
red/green nodes represent the upregulated/downregulated miRNA, and the blue nodes represent its targeted gene.
The prospect of using blood miRNAs and snoRNAs as biomarkers can be instrumental
in identifying patients with a higher risk of severity and mortality. In this context, we
calculated a correlation matrix to examine individual associations between the identified
common (Figure 3) and unique (Figure S1) differentially expressed miRNAs and snoRNAs
in severe cases, and routine laboratory tests such as complete blood count (CBC), glucose,
electrolytes, liver, and kidney function parameters and inflammatory markers. Several
of these clinical markers have been linked to prognosis in COVID-19 patients. We found
a significant correlation between several differentially expressed miRNAs and snoRNAs
and certain hematological and serological parameters, including WBC count (Figure 4A),
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lymphocyte (%) (Figure 4B), ANC, hematocrit, and albumin (Figure S2). Table 1 represents
a summary of patient’s demographics and clinical parameters used in the correlation
analysis. These observations can be validated in larger cohorts to help in the early detection
of patients at higher risk of severity, and thus in selection of dynamic treatment regimens.







Figure 3. Association of routine clinical markers with differentially expressed common miRNAs and snoRNAs. (A) Scatter 
plots of Log2 normalized expression values of miRNAs and snoRNAs in asymptomatic (n = 10, grey), mild (n = 10, light 
Figure 3. ssociation of routine clinical markers with iffere tially expressed common miRNAs
and snoRNAs. (A) Scatter plots of Log2 normalized expression values of miRNAs and snoRNAs
in asymptomatic (n = 10, grey), mild (n = 10, light orange), and severe (n = 9, blue) cases. The
comparison between different severity groups was done using the non-parametric Kruskal–Wallis
one-way ANOVA test, the median for asymptomatic, mild, and severe groups is reported as a
measure of centrality in each scatter plot. In each respective comparison, the p-adjusted values were
calculated using Holm’s sequential Bonferroni procedure for multiple hypothesis tests at an alpha
level of 0.05. (B) A correlation matrix of the 8 miRNAs and snoRNAs with associated clinical markers.
Each cell contains a correlation coefficient between the possible pairs of variables, namely Spearman’s
rho statistic calculated at a significance level of 0.05. Color scale ranges from blue (r = −1) to white
(r = 0) to red (r = 1).
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measurement. Each dot represents a single miRNA transcript, and those tagged with D letter show a deceased patient
measurement. For all statistical tests in the plots, the APA standard for statistical reporting is shown for Spearman correlation
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Table 1. Clinical characterization of asymptomatic, mild, and severe COVID-19 patients. Patients were grouped based on
clinical disease severity including severe requiring oxygen support and ICU admission, mild cases were recognized as
those with clinical symptoms and positive radiographic findings suggestive of pulmonary involvement. * ALP: Alkaline
phosphatase, ALT: Alanine aminotransferase, ANC: Absolute neutrophil count, APTT: Partial thromboplastin time, AST:
Aspartate aminotransferase, CK: Creatine kinase, CRP: C-reactive protein, Hct: Hematocrit, Hgb: Hemoglobin, IL-6:
Interleukin-6, INR: International normalized ratio, LDH: Lactate dehydrogenase, MCH: Mean cell hemoglobin, MCHC:
Mean corpuscular hemoglobin concentration, MCV: Mean corpuscular volume, MPV: Mean platelet volume, PDW: Platelet
distribution width, PT: Prothrombin time, RBC: Red blood cell count, RDW-CV: Red blood cell distribution width, WBC:
White blood cell count. Values are represented as: n (%), median (25–75%). For age: Mean ± SD is reported. The statistical
tests used to calculate p-value are Fisher’s exact test or Kruskal–Wallis rank sum test.
Characteristic * N Asymptomatic Mild Severe p-Value
Age [years] 29 54.50 ± 4.58 49.60 ± 9.18 58.22 ± 12.88 0.078
COVID-19 average CT 21 22.9 (21.5–29.2) 26.7 (23.4–29.4) 33.8 (26.8–34.1) 0.3
Diabetes Mellitus 29 6 (20.68%) 6 (20.68%) 6 (20.68%) >0.9
Glucose [mmol/L] 20 7.00 (6.25–14.40) 6.80 (6.27–8.12) 6.60 (6.40–10.60) 0.9
WBC [×103/µL] 27 6.3 (6.2–7.8) 5.5 (5.1–6.4) 11.9 (8.0–15.4) 0.014
Lymphocyte count [×103/µL] 27 2.10 (1.20–2.50) 1.30 (1.20–1.61) 1.10 (0.90–1.40) 0.2
Lymphocyte [%] 27 29 (24–33) 24 (21–31) 9 (5–14) 0.004
ANC [×103/µL] 27 3.6 (2.9–6.1) 3.6 (2.7–4.7) 7.7 (6.7–13.1) 0.005
Neutrophil [%] 21 56 (51–62) 66 (58–69) 83 (80–86) 0.012
Eosinophil count [×103/µL] 27 0.10 (0.00–0.27) 0.00 (0.00–0.00) 0.00 (0.00–0.10) 0.2
Eosinophil [%] 27 2.50 (0.90–3.40) 0.10 (0.00–0.80) 0.10 (0.00–0.80) 0.029
Monocyte count [×103/µL] 27 0.60 (0.60–0.70) 0.47 (0.40–0.50) 0.90 (0.80–1.00) 0.11
Monocyte [%] 27 8.70 (6.80–10.90) 9.00 (5.10–9.40) 5.60 (4.80–6.60) 0.14
Basophil count [×103/µL] 27 0.030 (0.030–0.040) 0.020 (0.020–0.050) 0.030 (0.010–0.040) 0.6
Basophil [%] 27 0.50 (0.40–0.80) 0.40 (0.20–0.50) 0.20 (0.10–0.40) 0.026
RBC [×106/µL] 27 5.10 (4.90–5.30) 5.00 (4.70–5.70) 3.80 (3.50–4.20) 0.011
Hgb [g/dL] 27 13.60 (13.50–15.20) 14.20 (13.60–16.00) 11.20 (9.90–12.60) 0.036
HbA1C [%] 18 8.70 (6.05–11.80) 7.00 (6.40–7.50) 6.00 (5.90–6.40) 0.4
Hct [%] 27 42 (40–43) 42 (40–47) 33 (30–38) 0.03
MCV [fL] 27 81.9 (81.0–87.0) 85.4 (82.2–91.2) 90.6 (86.4–91.2) 0.031
MCH [pg] 27 27.30 (26.50–29.50) 28.10 (27.90–30.50) 30.00 (29.40–30.30) 0.11
MCHC [g/dL] 27 33.30 (32.40–34.00) 33.60 (32.90–34.10) 33.50 (32.50–34.10) 0.8
RDW-CV [%] 27 13.00 (11.90–14.30) 14.20 (12.70–14.90) 13.90 (12.50–16.20) 0.3
MPV [fl] 27 10.20 (9.60–11.30) 10.80 (9.90–12.00) 10.40 (9.80–11.50) 0.8
Platelet [×109/L] 27 226 (200–251) 187 (161–324) 342 (223–363) 0.2
Ferritin [µg/L] 18 574 (574–574) 449 (210–804) 1131 (700–1856) 0.079
PDW [fl] 19 15.10 (15.10–15.10) 13.90 (12.00–15.80) 11.70 (11.00–14.20) 0.5
Fibrinogen [g/L] 11 6.80 (6.80–6.80) 4.60 (4.60–4.60) 5.10 (3.30–5.60) 0.5
D-Dimer [mg/L FEU] 16 1.55 (1.55–1.55) 0.40 (0.32–0.60) 2.65 (2.15–5.16) 0.036
APTT [second] 15 26 (26–26) 32 (29–35) 31 (31–36) 0.4
PT [second] 15 12.60 (12.60–12.60) 11.30 (11.10–11.50) 13.10 (12.60–13.50) 0.047
INR 15 1.10 (1.10–1.10) 1.00 (1.00–1.00) 1.10 (1.10–1.10) 0.057
CRP [mg/L] 27 3 (2–6) 21 (5–56) 26 (5–78) 0.063
IL-6 [pg/mL] 9 - 32 (20–34) 306 (137–476) 0.2
Total protein [g/L] 24 76 (66–77) 73 (69–75) 71 (68–72) 0.8
Albumin [g/L] 26 40 (36–42) 37 (35–39) 26 (24–29) 0.001
Chloride [mmol/L] 25 100.0 (97.5–101.5) 100.7 (98.0–103.0) 104.0 (102.0–107.0) 0.079
Magnesium [mmol/L] 14 0.85 (0.85–0.85) 0.79 (0.76–1.00) 0.94 (0.89–1.09) 0.4
Potassium [mmol/L] 26 4.80 (4.55–5.05) 4.10 (3.80–4.40) 4.20 (3.60–4.60) 0.11
Sodium [mmol/L] 27 136 (134–138) 138 (136–140) 139 (137–148) 0.2
Bicarbonate [mmol/L] 23 25.0 (24.0–26.0) 26.0 (21.5–27.0) 23.0 (22.0–28.0) >0.9
Calcium [mmol/L] 26 2.32 (2.25–2.37) 2.38 (2.34–2.44) 2.19 (2.14–2.30) 0.093
Adjusted calcium [mmol/L] 26 2.29 (2.24–2.39) 2.46 (2.35–2.46) 2.46 (2.45–2.52) 0.039
Vitamin D [ng/mL] 14 23 (20–24) 23 (14–32) 32 (23–39) 0.6
Procalcitonin [ng/mL] 13 0.25 (0.25–0.25) 0.38 (0.22–0.38) 0.26 (0.10–0.72) >0.9
Bilirubin [mg/dL] 25 5 (5–16) 9 (5–12) 10 (7–30) 0.4
Urea [mmol/L] 27 4 (4–6) 4 (4–5) 16 (10–20) <0.001
Uric acid [µmol/L] 19 295 (282–311) 229 (210–270) 355 (337–374) 0.2
Creatinine [µmol/L] 27 85 (73–99) 78 (69–100) 115 (83–168) 0.3
ALT [U/L] 23 18 (17–25) 34 (20–55) 59 (20–134) 0.2
AST [U/L] 20 23 (18–33) 27 (24–34) 34 (28–110) 0.2
CK [U/L] 14 129 (129–129) 97 (62–173) 103 (62–239) 0.8
ALP [U/L] 25 79 (66–115) 66 (61–93) 78 (45–143) 0.9
LDH [U/L] 14 183 (183–183) 337 (226–343) 332 (294–375) 0.3
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4. Discussion
Numerous differentially expressed miRNAs that are observed in this study have been
highlighted in host-pathogen interactions [28]. For instance, the family of let-7e/miR-
125a/miR-200 miRNAs have been reported to mediate ACE2 gene silencing [29]. Likewise,
KEGG enrichment analysis of the differentially expressed miRNAs targets has shown path-
ways involved in cellular proliferation, invasion, and apoptosis such as PI3K/AKT/mTOR
signaling. Whereas, inhibition of hsa-miR-1246 was demonstrated to reduce the cytotoxicity
of the Ebola virus glycoprotein in vitro. With multiple viral miRNAs sharing similarities
with the host miRNAs, in silico computational studies also uncovered several putative host
miRNAs involved in controlling viral replication and limiting disease progression [14,30–32].
These host miRNAs are predicted to bind viral sequences modulating cellular immune
responses, metabolic pathways, and inhibiting host miRNA maturation, thus facilitating
viral escape. Notably, we found 10 differentially expressed miRNAs targeting CDKN1A,
a potent cyclin-dependent kinase inhibitor, also known as p21. Interestingly ivermectin
inhibits p21-activated kinase 1 (PAK1), a serine/threonine kinase with oncogenic activity.
Caly et al. reported that ivermectin decreased SARS-CoV-2 RNA viral load in vitro by
5000-fold with a single treatment [33]. Another target of multiple differentially expressed
miRNAs is a suppressor of cytokine signaling 7 (SOCS7), which is known to exert an
inhibitory effect on interferon responses, thereby facilitating viral replication. Moreover,
insulin-like growth factor I receptor (IGF1R) was also regulated by 6 different differentially
expressed miRNAs detected in severely ill patients. IGF1R has been reported as a critical
regulator of transformation events, with high levels of expression in most malignancies,
where it acts as an anti-apoptotic agent by enhancing cell survival [34]. The MTGN analysis
suggests that SARS-CoV-2 infection is regulated by complicated miRNA regulatory net-
works, through multiple miRNAs targeting the same gene, and single miRNAs targeting
multiple genes.
Several studies have reported the fundamental role of interferons in COVID-19 dis-
ease severity [35]. Similarly, the identified miRNA in this study (Figure 2) suppresses
interferon signaling via binding interferon target genes. Additionally, multiple viruses,
including SARS-CoV-2 have been reported to enhance TGF-β signaling, which is known
to induce fibrosis and suppress adaptive immunity [36]. Our data suggests a modulation
of TGF-β signaling, via the surface receptors and canonical SMAD and MAPK pathways,
regulating adaptive immune responses and tissue repair. These findings are in line with
the relative lymphopenia reported in severe COVID-19 [1]. Captivatingly, siRNA studies
targeting candidate snoRNAs provide an evidence of their functional roles in virus–host
interactions against numerous viruses, while knock-down studies have demonstrated that
RNA viruses require specific C/D box snoRNAs for optimal replication [17]. Thus, a
validated COVID-19 miRNA and snoRNAs signature could be a useful tool to discriminate
COVID-19 infections from other respiratory viral infections, identify asymptomatic infec-
tions, and develop proteins and metabolite-based tests. This report provides a systematic
identification of miRNAs and snoRNAs profile in the blood of SARS-CoV-2 patients with
different disease severity, which expands on the previous computational approaches in
COVID-19-associated miRNAs and snoRNAs profiling. The patient samples were obtained
at a single time point ranging between 2–5 days post COVID-19 diagnosis in Qatar. The pa-
tients’ clinical history and lab investigations are well documented in the national healthcare
database (CERNER), based on which none of the studied patients were previously diag-
nosed with any chronic illness, cancer, or immunological disorder, except 18 patients who
had type 2 diabetes mellitus. Outcomes from our study can guide future studies involving
longitudinal sampling and analysis of circulatory miRNAs/snoRNAs that play a role in
disease resolution versus those involved in the development of long COVID. Moreover,
future studies with a larger sample size are needed to delineate miRNAs and snoRNAs
profiling in females, as well as in children. This study has extended our understanding
of the miRNAs and snoRNAs regulatory mechanisms underlying the pathogenesis of
SARS-CoV-2 infection, which can be explored further to produce promising therapies.
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Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/vaccines9101056/s1, Figure S1: Spearman correlation matrix of clinical markers with uniquely
DEMIs and snoRNAs in (A) severe versus mild and (B) severe versus asymptomatic comparisons.
Each cell contains a correlation coefficient between the possible pairs of variables, namely Spearman’s
rho statistic calculated at a significance level of 0.05. Color scale ranges from blue (r = −1) to white
(r = 0) to red (r = 1), Figure S2: Correlation between expression levels of common differentially
expressed miRNAs and snoRNAs (in both severe versus asymptomatic, and severe versus mild
comparisons) with (A) hematocrit, (B) absolute neutrophil count (ANC), and (C) albumin. Scatter
plots representation with x-axis as Log2 normalized transcript expression level and y-axis as the
clinical variable measurements. Each dot represents a single miRNA/ snoRNAs transcript. Dots that
are tagged with D letter represent a deceased patient measurement. For all statistical tests in the plots,
the APA standard for statistical reporting is shown for Spearman correlation test including evidence
in favor of null over alternative hypothesis, natural logarithm of Bayes Factor, p-value, Spearman’s
rank correlation coefficient, confidence intervals, and number of observations, Table S1: Differentially
expressed miRNAs and snoRNAs in severe versus asymptomatic and severe versus mild COVID-19
patients. Probe ID and Name, Transcript ID and accession, Log2 fold change, and FDR values are
shown, Table S2: Mature sequence of annotated differentially expressed miRNAs that are available
in miRbase. microRNA names, miRBase accession IDs, and microRNA mature sequences are shown.
For hsa-mir-453, reads that map to the annotated mir-4532 locus (many with one mismatch) map
exactly to annotated 28S rRNA sequences. The miRNA annotation is therefore likely to be false,
and the miRNA was therefore removed from the database, Table S3: Sequences of differentially
expressed small nucleolar RNAs in severe cases of COVID-19. Transcripts include snoRNA predicted
using sequences from RFAM and miRbase. The following snoRNAs transcript IDs are not annotated
in miRbase database, Table S4: Gene Set Enrichment Analysis (GSEA) of differentially expressed
miRNAs-targets via Enricher platform and Molecular Signatures Database (MSigDB). Each hallmark
gene set is an expressed signature derived by aggregating many MSigDB gene sets to characterize
reported biological states or processes, Table S5: Candidate genes that connect with more than 6
miRNA-target interactions using miRTarBase.
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